Sinopharm Group Co Equity 2025

Sinopharm Group Co Aktienanalyse

What does Sinopharm Group Co do?

Sinopharm Group Co Ltd is one of the largest Chinese companies in the healthcare industry and was founded in 1998. With its headquarters in Beijing, it has been a significant player in the global healthcare sector for many years and operates in various business areas. The company's history dates back to the 1940s when the original company, China National Pharmaceutical Industry Corporation, was founded. It was later transformed into China National Pharmaceutical Group and eventually renamed Sinopharm Group. Sinopharm's business model is designed to promote healthcare in China while expanding internationally. The company's key business areas include pharmaceutical research and development, drug manufacturing, and the import and export of pharmaceutical products. Overall, Sinopharm Group operates in various sectors, including the production of biological drugs, diagnostic products, medical devices, and medical consumables. Additionally, the company is involved in providing healthcare services such as hospital management and health tourism. An important part of Sinopharm's business is the export of drugs and other medical products. The company has established a global presence and maintains businesses and collaborations with companies in Asia, Europe, North America, and Africa. Furthermore, Sinopharm Group has established several subsidiaries to focus on specialized markets and products better. On the product side, Sinopharm offers a wide range of medications, health products, and medical devices. Some of the most well-known products include anti-cancer drugs, diabetes medications, vaccines, and blood products. The company also invests in research and development of new drugs and is involved in numerous clinical trials. The success of Sinopharm is also based on its close collaboration with the Chinese government. The company works closely with local and national authorities to meet the demand for healthcare products and services in China. The Chinese government also supports the company and promotes its expansion into other countries. Overall, Sinopharm Group has become a significant player in the global healthcare industry in recent years. The company has a strong presence in China and a growing international presence. With a wide range of products and services and a strong focus on research and development, Sinopharm Group is well-positioned to continue growing and adapting to the demands of the healthcare sector. Sinopharm Group Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Sinopharm Group Co's Equity

Sinopharm Group Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Sinopharm Group Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Sinopharm Group Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Sinopharm Group Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Sinopharm Group Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Sinopharm Group Co stock

What is the equity of Sinopharm Group Co this year?

Sinopharm Group Co has equity of 78.88 B CNY this year.

What was the equity of Sinopharm Group Co compared to the previous year?

The equity of Sinopharm Group Co has increased/decreased by 5.77% increased compared to the previous year.

What impact does a high equity have on investors of Sinopharm Group Co?

A high equity is advantageous for investors of Sinopharm Group Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Sinopharm Group Co?

A low equity can be a risk for investors of Sinopharm Group Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Sinopharm Group Co affect the company?

An increase in equity of Sinopharm Group Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Sinopharm Group Co affect the company?

A reduction in equity of Sinopharm Group Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Sinopharm Group Co?

Some factors that can affect the equity of Sinopharm Group Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Sinopharm Group Co so important for investors?

The equity of Sinopharm Group Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Sinopharm Group Co take to change the equity?

To change equity, Sinopharm Group Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Sinopharm Group Co pay?

Over the past 12 months, Sinopharm Group Co paid a dividend of 0.96 CNY . This corresponds to a dividend yield of about 5.38 %. For the coming 12 months, Sinopharm Group Co is expected to pay a dividend of 1.04 CNY.

What is the dividend yield of Sinopharm Group Co?

The current dividend yield of Sinopharm Group Co is 5.38 %.

When does Sinopharm Group Co pay dividends?

Sinopharm Group Co pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Sinopharm Group Co?

Sinopharm Group Co paid dividends every year for the past 20 years.

What is the dividend of Sinopharm Group Co?

For the upcoming 12 months, dividends amounting to 1.04 CNY are expected. This corresponds to a dividend yield of 5.84 %.

In which sector is Sinopharm Group Co located?

Sinopharm Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sinopharm Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sinopharm Group Co from 8/12/2025 amounting to 0.739 CNY, you needed to have the stock in your portfolio before the ex-date on 6/16/2025.

When did Sinopharm Group Co pay the last dividend?

The last dividend was paid out on 8/12/2025.

What was the dividend of Sinopharm Group Co in the year 2024?

In the year 2024, Sinopharm Group Co distributed 0.9 CNY as dividends.

In which currency does Sinopharm Group Co pay out the dividend?

The dividends of Sinopharm Group Co are distributed in CNY.